(SHP) Shire

Another strong year for Shire with revenues exceeding $4 billion for the first
time and Non GAAP EPS up 26% to $5.34.



Good 2012 earnings growth expected.



February 9, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces results for the year to December 31, 2011.



Financial Highlights Full Year 2011(1)

Product sales $3,950 million +26%

Total revenues $4,263 million +23%



Non GAAP operating income $1,357 million +27%

US GAAP operating income $1,109 million +40%



Non GAAP diluted earnings per ADS $5.34 +26%

US GAAP diluted earnings per ADS $4.53 +43%



Non GAAP cash generation $1,391 million +3%

Non GAAP free cash flow $879 million +11%

US GAAP net cash provided by operating activities $1,074 million +12%






(1) Percentages compare to the full financial year 2010.



The Non GAAP financial measures included within this release are explained on
page 27, and are reconciled to the most directly comparable financial measures
prepared in accordance with US GAAP on pages 22 - 26.



Angus Russell, Chief Executive Officer, commented:



"Shire has had another strong year - our strategy of focusing on meeting the
needs of patients, physicians and payors to deliver value to the healthcare
system has led to growing sales across our balanced portfolio of differentiated
products. In 2011 our total revenues topped $4 billion for the first time.



In ADHD, sales of both VYVANSE and INTUNIV significantly outpaced the 10%
growth of the US ADHD market. Our geographic expansion is progressing well,
with the launch of VENVANSE in Brazil, an agreement with Shionogi to co-develop
ADHD medicines in Japan, and our recent filing of VENVANSE in Europe.



Our sales of VPRIV for Gaucher disease were up 79%, REPLAGAL for Fabry disease
was up 35% and ELAPRASE for Hunter Syndrome was up 15%. FIRAZYR for HAE has
progressed well following its US launch. In addition, the regulatory processes
are progressing well at our new biologics manufacturing facility in Lexington,
Massachusetts which will soon enable us to significantly increase capacity to
meet growing global demand.



In our Regenerative Medicine business, DERMAGRAFT, for diabetic foot ulcers,
has performed strongly, generating sales of $105 million since we acquired
Advanced BioHealing Inc. in late June.



We also saw good progress in our pipeline. New uses for VYVANSE, a diverticular
disease indication for LIALDA, and a new intrathecal mode of protein delivery
for rare genetic CNS diseases are some of the novel and exciting treatments
we're developing and hope to bring to patients in the coming years.



Supported by our strong cash generation, we will continue to invest in growth
prospects that will further leverage our established infrastructure. We expect
2012 to be a year of good earnings growth, as we aim to deliver increasing
value to all our stakeholders."


FINANCIAL SUMMARY



Full Year 2011 Unaudited Results

Full Year 2011 Full Year 2010
US GAAP Adjustments Non GAAP US GAAP Adjustments Non GAAP

$M $M $M $M $M $M

Total revenues 4,263 - 4,263 3,471 - 3,471

Operating
income 1,109 248 1,357 794 278 1,072


Diluted
earnings per
ADS $4.53 $0.81 $5.34 $3.16 $1.07 $4.23






Product sales in 2011 were up 26% to $3,950 million (2010: $3,128 million). On
a constant exchange rate ("CER") basis, which is a Non GAAP measure, product
sales were up 24%.

Product sales growth was generated from across the portfolio, particularly
VYVANSE® (up 27% to $805 million), ADDERALL XR® (up 48% to $533 million),
REPLAGAL® (up 35% to $475 million), ELAPRASE® (up 15% to $465 million), LIALDA®
/MEZAVANT® (up 27% to $372 million) andVPRIV® (up 79% to $256 million). Product
sales in 2011 also benefited from $105 million of DERMAGRAFT® sales made
subsequent tothe acquisition of Advanced BioHealing Inc. ("ABH").

Total revenues in 2011 exceeded $4 billion for the first time, increasing by
23% (CER: up 21%) to $4,263 million (2010: $3,471 million). The strong product
sales growth more than offset decreased royalties and other revenues, down 9%
due to lower 3TC® and ZEFFIX®royalties.



Non GAAP operating income was up 27% to $1,357 million (2010: $1,072 million),
as total revenues grew at a faster rate than Research and Development ("R&D")
and Selling, General and Administrative ("SG&A") expenditure.

Combined Non GAAP R&D and SG&A expenditure increased by 19% in 2011, as we
increased investment in a number of early and late stage development programs,
absorbed the operating costs from our recent acquisitions of ABH and Movetis
N.V. ("Movetis"), and supported our product launches and continued growth.

Non GAAP diluted earnings per American Depositary Share ("ADS") were up 26% to
$5.34 (2010: $4.23), due to higher Non GAAP operating income and a lower Non
GAAP effective tax rate of 22% in 2011 (2010: 23%).

On a US GAAP basis, operating income was up 40% to $1,109 million (2010: $794
million), as total revenues grew at a faster rate than R&D and SG&A
expenditure. US GAAP operating income in 2010 included impairment charges
recorded on the divestment of DAYTRANA and an up-front payment of $45 million
to Acceleron Pharma Inc. ("Acceleron").

US GAAP diluted earnings per ADS were up 43% to $4.53 (2010: $3.16) due to
higher US GAAP operating income and a lower US GAAP effective tax rate in 2011
of 21% (2010: 24%).

Cash generation, a Non GAAP measure, was up 3% to $1,391 million (2010: $1,353
million). Cash generation in 2011 was adversely affected by the timing and
quantum of both sales deduction and operating expenditure payments and lower
royalty receipts, which offset higher cash receipts from higher gross product
sales.

Free cash flow, a Non GAAP measure, was up 11% to $879 million (2010: $795
million) due to higher cash generation and lower cash tax payments in 2011
compared to 2010. On a US GAAP basis, net cash provided by operating activities
was up 12% to $1,074 million (2010: $955 million).

Net debt at December 31, 2011 was $468 million (December 31, 2010: $531
million), a reduction of $63 million. Free cash flow and receipts from the
divestments of non-core investments has reduced net debt and funded the
acquisition of ABH, the acquisition of shares by the Employee Share Ownership
Trust ("ESOT") and dividend payments.



Net debt includes Shire's $1,100 million convertible bonds (the "Bonds"), which
are due in 2014, or redeemable at the option of the Bond holder in May 2012
(the "Put Option"). Shire does not consider it likely that the Put Option will
be exercised. However, if the Bonds were redeemed in full in 2012, Shire's
existing cash, its $1,200 million credit facility and free cashflow would be
sufficient to fund repayment.




2012 OUTLOOK



We enter 2012 with good momentum following a strong performance in 2011. We
believe that our product portfolio will continue to deliver sales growth in the
low to mid teens range, despite the expected decline in sales of CARBATROL and
REMINYL following their loss of exclusivity. Combining this with royalties and
other revenues, which are expected to be 15%-25% lower year on year, we are
still forecasting good revenue growth.

We anticipate that gross margins will be marginally lower in 2012 reflecting
the full year impact of our acquisition of ABH.

In 2012 we will continue to advance our promising pipeline of early and late
stage programs and invest behind the continued international expansion of our
commercial activities. As we support this investment and also absorb a full
year of ABH's operating costs, we expect combined Non GAAP R&D and SG&A
spending to increase by 10-12% compared to 2011.

We expect our tax rate for 2012 to be in the range of 20 to 22%.

Overall, we look forward to good earnings growth in 2012.

In recent weeks we have seen continuing foreign exchange volatility. Our 2012
Outlook is based on exchange rates as at January 31, 2012 (Euro:$1.31, £:$1.58,
CHF:$1.09). The impact on our revenue and earnings of a 10% appreciation of the
US Dollar against these and other major currencies would be:



Revenue Earnings

Euro (1.5%) (2.2%)

Sterling (0.4%) 1.0%

Swiss Franc 0.0% 1.8%

Other Currencies (0.7%) (1.3%)





FINANCIAL SUMMARY



Fourth Quarter 2011 Unaudited Results

Financial Highlights Fourth Quarter 2011(1)

Product sales $1,049 million +23%

Total revenues $1,142 million +23%



Non GAAP operating income $369 million +54%

US GAAP operating income $304 million +55%



Non GAAP diluted earnings per ADS $1.51 +47%

US GAAP diluted earnings per ADS $1.33 +51%



Non GAAP cash generation $447 million +13%

Non GAAP free cash flow $351 million +26%

US GAAP net cash provided by operating activities $409 million +19%






(1) Percentages compare to equivalent 2010 period.



Product sales in Q4 2011 were up 23% (CER: up 24%) to $1,049 million (Q4 2010:
$851 million).

Product sales growth was experienced across the portfolio, particularly VYVANSE
(up 20% to $217 million), ADDERALL XR (up 40% to $125 million), ELAPRASE(up 17%
to $124 million) and INTUNIV® (up 52% to $65 million). Product sales of
DERMAGRAFT totaled $53 million and represented six percentage points of our
reported product sales growth in Q4 2011.

Total revenues were up 23%, to $1,142 million (Q4 2010: $931 million), due to
higher product sales and higher royalties and other revenues (up 17%). Higher
royalties on ADDERALL XR and FOSRENOL® in Q4 2011 more than offset the
continued decline in 3TC and ZEFFIX royalties.



Non GAAP operating income was up 54% to $369 million (Q4 2010: $239 million),
due to higher total revenues and lower Non GAAP operating expense ratios in Q4
2011 compared to the relatively higher ratios seen in Q4 2010.



Combined Non GAAP R&D and SG&A increased 9% in Q4 2011 as we continued to
increase investment in our development programs (particularly for VYVANSE new
uses and Sanfilippo), absorbed ABH's operating costs and supported our product
launches and continued growth.



On a US GAAP basis, operating income in Q4 2011 was up 55% to $304 million (Q4
2010: $196 million).



Non GAAP diluted earnings per ADS were up 47% to $1.51 (Q4 2010: $1.03), due to
the higher Non GAAP operating income, partially offset by a higher Non GAAP
effective tax rate of 19% for Q4 2011 (Q4 2010: 16%) as the favorable effect of
certain tax credits in Q4 2010 were not repeated in Q4 2011. On a US GAAP basis
diluted earnings per ADS were up 51% to $1.33 (Q4 2010: $0.88).



Cash generation, a Non GAAP measure, was up 13% to $447 million (Q4 2010: $394
million). Higher cash receipts from gross product sales were partially offset
by the timing and quantum of cash payments on operating expenditure and sales
deduction payments in Q4 2011.



Free cash flow, also a Non GAAP measure, was up 26% to $351 million (Q4 2010:
$278 million) due to higher cash generation and lower cash tax payments in Q4
2011.



On a US GAAP basis, net cash provided by operating activities was up 19% to
$409 million (Q4 2010: $343 million).


FOURTH QUARTER 2011 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS



Products



VPRIV and REPLAGAL Manufacturing Update

On November 22, 2011 Shire announced that it had submitted regulatory filings
with both the European Medicines Agency and the US Food and Drug Administration
("FDA") for the production of VPRIV in its new manufacturing facility in
Lexington, Massachusetts. Required inspections have been completed. Subject to
regulatory approval, which is anticipated in early 2012, Shire expects the new
plant to increase manufacturing capacity significantly and allow for increased
global supply of VPRIV. These approvals will also make available further
capacity for the manufacture of REPLAGAL at Shire's Alewife facility, where
both VPRIV and REPLAGAL are currently manufactured.



Shire is committed to providing current patients with uninterrupted long-term
access to treatment at the dose and frequency prescribed by their physician.



RESOLOR® - for the symptomatic treatment of chronic constipation



On January 10, 2012 Shire announced that it had acquired the rights to develop
and market RESOLOR in the US in an agreement with Janssen Pharmaceutica N.V.,
part of the Johnson & Johnson Group.



VYVANSE - for the treatment of Attention Deficit Hyperactivity Disorder
("ADHD") in adults



On January 31, 2012, the FDA approved VYVANSE for the maintenance treatment of
ADHD in adults. VYVANSE is the first product in its class with this indication.




Pipeline



HGT - 3010 for Sanfilippo B Syndrome (Mucopolysaccharidosis IIIB)



Shire has initiated early development of a product for the treatment of
Sanfilippo B Syndrome, a severe, progressive, neurodegenerative disorder with
no current treatment. The HGT-3010 program is entering preclinical studies for
an enzyme replacement therapy delivered intrathecally, and a natural history
study will be conducted.



REPLAGAL - for the treatment of Fabry disease

In November 2011, Shire completed a rolling Biologics License Application
("BLA") for REPLAGAL in the US. The FDA has accepted the BLA under Priority
Review and assigned an action date of May 17, 2012. Currently there are over
2,800 patients receiving REPLAGAL worldwide.



Lisdexamfetamine dimesylate ("LDX", currently marketed as VYVANSE in the US for
the treatment of ADHD) - for the treatment of inadequate response in Major
Depressive Disorder ("MDD")

On December 8, 2011 Shire announced positive Phase 2 results in a clinical
study to assess the efficacy of VYVANSE as adjunctive therapy to primary
antidepressant treatment in improving executive functioning in adults with
partial or full remission of recurrent MDD and significant, persistent
cognitive impairments. Improvements were seen in both subjective and objective
measures of cognitive dysfunction, and noted by all involved in treatment:
patients, their caregivers, and physicians. There are no approved treatments
for the residual, yet clinically impairing symptoms of cognitive impairment in
MDD.



A Phase 3 program to assess the efficacy and safety of VYVANSE as adjunctive
therapy in patients with MDD was initiated in the fourth quarter of 2011.



VENVANSE® - for the treatment of ADHD in Europe in children and adolescents (6
- 17 years old)

On January 5, 2012 Shire announced the acceptance for review by the UK
Medicines Healthcare products Regulatory Agency ("MHRA"), of the once-daily
ADHD medicinal product VENVANSE. VENVANSE is currently approved in the US as
VYVANSE for the treatment of ADHD. The MHRA has agreed to act as the Reference
Member State for this Decentralised Procedure which will initially include
eight European countries. This application follows the successful completion of
the European Phase 3 study of VENVANSE in children and adolescents with ADHD in
2011.



INTUNIV - for the treatment of ADHD in children and adolescents (6 - 17 years
old) in Canada



On December 23, 2011, a New Drug Submission for INTUNIV was accepted for
screening by Health Canada seeking approval for use as monotherapy or
co-administered with a stimulant in children and adolescents with ADHD. This is
the first regulatory submission for approval of INTUNIV outside of the US.


OTHER FOURTH QUARTER AND RECENT DEVELOPMENTS



Strategic Partnership with Shionogi & Co Ltd ("Shionogi") for ADHD Medicines in
Japan

On November 18, 2011 Shire announced that it had entered into an agreement with
Shionogi to co-develop and co-commercialize certain of Shire's ADHD medicines
in Japan. Shionogi paid Shire an up front fee and will share costs with Shire
in exchange for rights to jointly co-develop and co-commercialize the products
upon approval for the Japanese market. Shionogi is a leading Japanese
pharmaceutical company with an expertise in developing medicines for the
central nervous system, among other therapeutic areas. Working together with
the Shionogi team, Shire believes the path to regulatory approval, market
development and commercialization for ADHD medicines will be more effective and
efficient.



Collaboration and license agreement with Sangamo BioSciences, Inc ("Sangamo")
to develop therapeutics for hemophilia

On February 1, 2012 Shire and Sangamo announced that they have entered into a
collaboration and license agreement to develop therapeutics for hemophilia and
other monogenic diseases based on Sangamo's zinc finger DNA-binding protein
("ZFP") technology. Shire will receive exclusive world-wide rights to ZFP
Therapeutics® designed to target four genes in hemophilia and will also receive
the right to designate three additional gene targets. Sangamo is responsible
for all activities through submission of Investigational New Drug Applications
and European Clinical Trial Applications for each product and Shire will
reimburse Sangamo for its internal and external research program-related costs.
Shire is responsible for clinical development and commercialization of products
arising from the alliance. Shire will pay Sangamo an upfront fee followed by
research, regulatory, development and commercial milestone payments, and
royalties on product sales.




BOARD AND COMMITTEE CHANGES



Dr Jeffrey Leiden stepped down from the Shire Board and its Board Committees on
January 31, 2012. Dr Leiden previously chaired Shire's Science & Technology
Committee and was a member of Shire's Remuneration and Nomination Committees.
Dr Leiden had been a non executive director of Shire since January 2007.



Mr William Burns has been appointed as a member of the Science & Technology
Committee with effect from February 8, 2012.



Ms Anne Minto has been appointed as a member of the Nomination Committee with
effect from February 8, 2012.




DIVIDEND



For the six months to December 31, 2011 the Board has resolved to pay an
interim dividend of 12.59 US cents per ordinary share (2010: 10.85 US cents per
ordinary share).



Dividend payments will be made in Pounds Sterling to ordinary shareholders and
in US Dollars to holders of ADSs. A dividend of 7.96 pence per ordinary share
(2010: 6.73 pence) and 37.77 US cents per ADS (2010: 32.55 US cents) will be
paid on April 12, 2012 to shareholders on the register as at the close of
business on March 9, 2012.



Together with the first interim payment of 2.48 US cents per ordinary share
(2010: 2.25 US cents per ordinary share), this represents total dividends for
2011 of 15.07 US cents per ordinary share (2010: 13.10 US cents per ordinary
share), an increase of 15% in US Dollar terms.


ADDITIONAL INFORMATION



The following additional information is included in this press release:

Page

Overview of Full Year 2011 Financial Results 9

Financial Information 13

Non GAAP Reconciliations 22

Safe Harbor Statement 26

Explanation of Non GAAP Measures 27

Trademarks 27






For further information please contact:



Investor Relations

- Eric Rojas erojas@shire.com +1 781 482 0999


- Sarah Elton-Farr seltonfarr@shire.com +44 1256 894 157

Media

- Jessica Mann (Corporate) jmann@shire.com +44 1256 894 280

- Gwen Fisher (Specialty Pharma) gfisher@shire.com +1 484 595 9836

- Jessica Cotrone (Human Genetic
Therapies) jcotrone@shire.com +1 781 482 9538

- Lindsey Hart (Regenerative Medicine) lhart@abh.com +1 615 250 3311








Dial in details for the live conference call for investors 14:00 GMT/9:00 EST
on February 9, 2012:



UKdial in: 0800 077 8492 or 0844 335 0351

US dial in: 1 866 8048688 or 1 718 3541175

International dial in: +44 844 335 0351

Password/Conf ID: 368477

Live Webcast: http://www.shire.com/shireplc/en/
investors


OVERVIEW OF FULL YEAR 2011 FINANCIAL RESULTS



1. Product sales



For the year to December 31, 2011 product sales increased by 26% to $3,950.2
million (2010: $3,128.2 million) and represented 93% of total revenues (2010:
90%). On a CER basis product sales were up 24%.



Product Highlights Year on year growth

US Rx US Exit Market Share
Product Sales $M Sales CER (1) (1)



VYVANSE 805.0 +27% +27% +21% 17%

ADDERALL XR 532.8 +48% +47% +11% 7%

REPLAGAL 475.2 +35% +30% n/a(3) n/a(3)

ELAPRASE 464.9 +15% +12% n/a(2) n/a(2)

LIALDA/MEZAVANT 372.1 +27% +26% +9% 21%

VPRIV 256.2 +79% +76% n/a(2) n/a(2)

PENTASA® 251.4 +7% +7% -2% 14%

INTUNIV 223.0 +34% +34% +78% 4%

FOSRENOL 166.9 -8% -11% -16% 5%

DERMAGRAFT(4) 105.3 n/a n/a n/a(2) n/a(2)

FIRAZYR® 33.0 +197% +188% n/a(2) n/a(2)

RESOLOR 6.1 n/a n/a n/a(3) n/a(3)

-25%
OTHER 258.3 (5) -28% n/a n/a

Total product
sales 3,950.2 +26% +24%






(1) Data provided by IMS Health National Prescription Audit ("IMS
NPA"). Exit market share represents the average US market share in the month
ended December 31, 2011.

(2) IMS NPA Data not available.

(3) Not sold in the US in 2011.

(4) DERMAGRAFT was acquired by Shire on June 28, 2011 (the sales
included above are for the period since acquisition).

(5) 2010 included DAYTRANA product sales of $49.4 million.



VYVANSE - ADHD

VYVANSE product sales grew strongly in 2011 as a result of higher prescription
demand, due to an increase in VYVANSE's market share and growth in US ADHD
market (+10%), and the effect of a price increase taken in 2011. These factors
more than offset the effect of de-stocking and higher sales deductions in 2011
compared to 2010.



ADDERALL XR - ADHD



ADDERALL XR product sales grew by 48%, or $172 million, principally as a result
of lower sales deductions as a percentage of branded gross product sales,
increases in US prescription demand (in line with growth in the US ADHD market)
and a price increase taken during 2011.

Sales deductions in 2011 represented 57% of branded gross product sales (2010:
65% of branded gross product sales). The decrease in sales deductions was
primarily due to the lowering of our estimate of inventory in the US retail
pipeline and the related sales deduction reserve in Q3 2011 (representing 2% of
gross product sales in 2011) and the mix of customer sales affecting the rebate
calculation. The eight percentage point decrease in sales deductions (as a
percentage of branded gross product sales) contributed $85 million to ADDERALL
XR's net product sales in 2011. ADDERALL XR sales deductions in 2012 are
expected to be in the range of 60-65%.



REPLAGAL - Fabry disease

The 35% growth (30% on a CER basis) in REPLAGAL product sales was driven by the
treatment of new patients, being both naïve patients and switches from patients
being treated with FABRAZYME®. Reported REPLAGAL sales also benefited from
favorable foreign exchange, due to the weaker US dollar over the course of 2011
compared to 2010.



ELAPRASE- Hunter syndrome

Product sales for ELAPRASE increased as a result of increased patients on
therapy across all regions in which ELAPRASE is sold. Reported ELAPRASE sales
also benefited from favorable foreign exchange.



LIALDA/MEZAVANT - Ulcerative colitis

The growth in product sales for LIALDA/MEZAVANT in 2011 was primarily driven by
higher US prescription demand following increases in US market share, a price
increase taken since Q4 2010 and the effect of stocking in 2011 compared to
de-stocking in 2010.



VPRIV - Gaucher disease



VPRIV product sales growth was driven by the treatment of new patients, being
both naïve patients and patients switching from CEREZYME®. Reported sales also
benefited from favorable foreign exchange.



PENTASA - Ulcerative colitis

Product sales of PENTASA continued to grow despite lower US prescription
demand, due to the impact of a price increase taken during 2011.



INTUNIV - ADHD



INTUNIV product sales were up 34% compared to 2010, primarily driven by
significant growth in US prescription demand together with a price increase
taken during 2011. These positive factors were offset by lower stocking and
higher sales deductions in 2011 compared to 2010, and the effect of the
inclusion of launch stocking shipments within reported 2010 product sales.



FOSRENOL - Hyperphosphatemia



Product sales of FOSRENOL outside the US decreased marginally primarily because
of mandatory price reductions that were imposed in several key markets. Product
sales of FOSRENOL in the US decreased due to lower US prescription demand and
higher sales deductions compared to 2010, which more than offset a 2011 price
increase.



DERMAGRAFT - Diabetic Foot Ulcers ("DFU")



DERMAGRAFT continues to see strong revenue growth in the US, up 33% for the
full year 2011 compared to the full year 2010(1). The growth resulted from a
combination of an expanding US diabetic population, continued adoption of
DERMAGRAFT as a treatment for DFU, and the continued investment in marketing
programs and additional sales representatives to market the product.



(1) Shire acquired DERMAGRAFT through its acquisition of ABH on June 28, 2011.



FIRAZYR - Hereditary Angioedema



The significant growth rate in global product sales in 2011 follows the
successful launch of FIRAZYR in the US in August 2011 and the approval for
self-administration in the EU in March 2011.




2. Royalties



Product Royalties to Shire $M Year on year growth CER

ADDERALL XR 107.1 7% 7%

3TC and Zeffix 82.7 -46% -47%

FOSRENOL 46.5 74% 74%

Other 47.2 0% -3%

Total 283.5 -14% -14%




Royalty income decreased in 2011 compared to 2010 as lower royalties from 3TC
and ZEFFIX more than offset higher royalty income from ADDERALL XR and
FOSRENOL.



Royalty income from 3TC and ZEFFIX continues to be adversely impacted by
increased competition from other products. Additionally, with effect from Q2
2011, Shire has not recognized royalty income for 3TC and ZEFFIX for certain
territories due to a disagreement between GSK and Shire about how the relevant
royalty rates should be applied given the expiry dates of certain patents. GSK
and Shire are holding discussions in order to seek to resolve the disagreement.


3. Financial details



Cost of product sales


2011 2010
% of product % of product
$M sales $M sales

Cost of product sales 588.1 15% 463.4 15%

Transfer of manufacturing from
Owings Mills (11.3) (30.4)

Unwind of DERMAGRAFT inventory
fair value adjustment (11.0) -

Depreciation (33.2) (12.4)

Non GAAP cost of product sales 532.6 13% 420.6 13%






Cost of product sales as a percentage of product sales remained constant as the
effect of slightly higher margins from existing products were offset by the
inclusion of DERMAGRAFT into Shire's portfolio in 2011.



R&D


2011 2010
% of product % of product
$M sales $M sales

R&D 770.7 20% 661.5 21%

Impairment of intangible (16.0) -
assets

Up-front payment to - (45.0)
Acceleron

Depreciation (25.2) (19.0)

Non GAAP R&D 729.5 18% 597.5 19%






Non GAAP R&D in 2011 was up $132.0 million, or 22%, as we continue to increase
our investment in a number of targeted R&D programs, including new uses for
VYVANSE, Sanfilippo and other development programs. Non GAAP R&D in 2011 also
included a full year of Movetis's development programs and ABH's expenditure in
the second half of 2011, together with the adverse impact of foreign exchange
in 2011 compared to 2010. On a US GAAP basis, R&D increased by $109.2 million,
or 17% over 2010.



SG&A


2011 2010
% of product % of product
$M sales $M sales

SG&A 1,751.4 44% 1,526.3 49%

Intangible asset (165.0) (133.5)
amortization

Impairment of intangible - (42.7)
assets

Depreciation (63.1) (62.1)

Non GAAP SG&A 1,523.3 39% 1,288.0 41%






Non GAAP SG&A increased by $235.3 million, or 18%, as we continue to support
the growth of our existing and recently launched products along with developing
our international infrastructure. Non GAAP SG&A in 2011 also included a full
year of Movetis's operating costs, ABH's expenditure in the second half of 2011
and the adverse impact of foreign exchange in 2011 compared to 2010. On a US
GAAP basis, SG&A increased by $225.1 million, or 15% over 2010.



Reorganization costs

For the year to December 31, 2011 Shire recorded reorganization costs of $24.3
million (2010: $34.3 million) relating to the transfer of manufacturing from
its Owings Mills facility to a third party and the establishment of an
international commercial hub in Switzerland.




Integration and acquisition costs



For the year to December 31, 2011 Shire recorded integration and acquisition
costs of $13.7 million (2010: $8.0 million), which related to the acquisition
and integration of ABH ($13.6 million) and the integration of Movetis ($8.3
million), partially offset by an adjustment to contingent consideration payable
for EQUASYM® ($8.2 million). In 2010 integration and acquisition costs
primarily related to the acquisition of Movetis.



Interest expense



For the year to December 31, 2011 Shire incurred interest expense of $39.1
million (2010: $35.1 million). Interest expense principally relates to the
coupon and amortization of issue costs on Shire's $1,100 million 2.75%
convertible bonds due 2014.



Other expense, net



2011 2010

$M $M

Other income, net 18.1 7.9

Gain on sale of investments (23.5) (11.1)

Impairment of available for sale securities 2.4 -

Non GAAP other expense, net (3.0) (3.2)






On a US GAAP basis Shire recognized other income, net of $18.1 million (2010:
$7.9 million). US GAAP other income in 2011 includes a gain of $23.5 million
arising on the disposal of substantially all of Shire's holding in Vertex
Pharmaceuticals Inc. ("Vertex") (Shire received these shares as partial
consideration for its investment in ViroChem Pharma Inc. ("ViroChem"),
following ViroChem being acquired by Vertex). US GAAP other income in 2010
includes a gain of $11.1 million arising on the disposal of Shire's investment
in ViroChem.



Taxation



The effective tax rate on Non GAAP income in 2011 was 22% (2010: 23%). The Non
GAAP effective tax rate in 2011 is lower than 2010 due to favourable changes in
profit mix, including the full year effect in 2011 of our establishment of an
international commercial hub in Switzerland during Q4 2010.



The effective tax rate under US GAAP was 21% (2010: 24%). The US GAAP effective
tax rate in 2011 is lower than 2010 due to favourable changes in profit mix in
2011, together with the effect of certain expenses in 2010 (including the
up-front payment to Acceleron) being incurred in territories with a tax rate
lower than Shire's effective tax rate.


FINANCIAL INFORMATION



TABLE OF CONTENTS



Page



Unaudited US GAAP Consolidated Balance Sheets 14



Unaudited US GAAP Consolidated Statements of Income 15



Unaudited US GAAP Consolidated Statements of Cash Flows 17



Selected Notes to the Unaudited US GAAP Financial Statements

(1) Earnings per share 19

(2) Analysis of revenues 20



Non GAAP reconciliation 22



Unaudited US GAAP financial position as of December 31, 2011
Consolidated Balance Sheets

December December
31, 31,
2011 2010

$M $M

ASSETS

Current assets:

Cash and cash equivalents 620.0 550.6

Restricted cash 20.6 26.8

Accounts receivable, net 845.0 692.5

Inventories 340.1 260.0

Deferred tax asset 207.6 182.0

Prepaid expenses and other current assets 174.9 168.4



Total current assets 2,208.2 1,880.3



Non-current assets:

Investments 29.9 101.6

Property, plant and equipment ("PP&E"), net 932.1 853.4

Goodwill 592.6 402.5

Other intangible assets, net 2,493.0 1,978.9

Deferred tax asset 50.7 110.4

Other non-current assets 73.7 60.5



Total assets 6,380.2 5,387.6



LIABILITIES AND EQUITY

Current liabilities:

Accounts payable and accrued expenses 1,370.5 1,239.3

Convertible bonds 1,100.0 -

Deferred tax liability - 4.4

Other current liabilities 63.8 49.6



Total current liabilities 2,534.3 1,293.3



Non-current liabilities:

Convertible bonds - 1,100.0

Deferred tax liability 516.6 352.1

Other non-current liabilities 144.3 190.8



Total liabilities 3,195.2 2,936.2



Equity:

Common stock of 5p par value; 1,000 million shares
authorized; and 562.5 million shares issued and outstanding
(2010: 1,000 million shares authorized; and 562.2 million
shares issued and outstanding) 55.7 55.7

Additional paid-in capital 2,853.3 2,746.4

Treasury stock: 11.8 million shares (2010: 14.0 million) (287.2) (276.1)

Accumulated other comprehensive income 60.3 85.7

Retained earnings/(accumulated deficit) 502.9 (160.3)



Total equity 3,185.0 2,451.4



Total liabilities and equity 6,380.2 5,387.6



Unaudited US GAAP results for the three months and year to December 31, 2011
Consolidated Statements of Income



3 months 3 months
to to Year to Year to
December December December December
31, 31, 31, 31,
2011 2010 2011 2010

$M $M $M $M

Revenues:

Product sales 1,049.2 851.4 3,950.2 3,128.2

Royalties 83.7 73.6 283.5 328.1

Other revenues 9.3 6.2 29.7 14.8

Total revenues 1,142.2 931.2 4,263.4 3,471.1



Costs and expenses:

Cost of product sales(1) 153.4 129.7 588.1 463.4

R&D(1) 214.4 185.6 770.7 661.5

SG&A(1) 456.1 419.7 1,751.4 1,526.3

Loss/(gain) on sale of product
rights 2.2 (12.4) 6.0 (16.5)

Reorganization costs 6.3 11.0 24.3 34.3

Integration and acquisition costs 5.8 1.6 13.7 8.0

Total operating expenses 838.2 735.2 3,154.2 2,677.0



Operating income 304.0 196.0 1,109.2 794.1



Interest income 0.4 0.5 1.9 2.4

Interest expense (10.3) (9.5) (39.1) (35.1)

Other income/(expense), net 2.2 (1.2) 18.1 7.9

Total other expense, net (7.7) (10.2) (19.1) (24.8)



Income before income taxes and
equity in (losses)/earnings of
equity method investees 296.3 185.8 1,090.1 769.3

Income taxes (40.3) (21.9) (227.6) (182.7)

Equity in (losses)/earnings of
equity method investees, net of
taxes (0.7) 1.2 2.5 1.4

Net income 255.3 165.1 865.0 588.0




Cost of product sales includes amortization of intangible assets relating to
favorable manufacturing contracts of $0.4 million for the three months to
December 31, 2011 (2010: $0.4 million) and $1.7 million for the year to
December 31, 2011 (2010: $1.7 million). R&D costs include intangible assets
impairment charges of $16.0 million for the year to December 31, 2011 (2010:
$nil). SG&A costs include amortization and impairment charges of intangible
assets relating to intellectual property rights acquired of $45.9 million for
the three months to December 31, 2011 (2010: $33.9 million) and $165.0 million
for the year to December 31, 2011 (2010: $176.2 million).




Unaudited US GAAP results for the three months and year to December 31, 2011
Consolidated Statements of Income (continued)



3 months 3 months
to to Year to Year to
December December December December
31, 31, 31, 31,
2011 2010 2011 2010



Earnings per ordinary share -
basic 46.4c 30.1c 156.9c 107.7c



Earnings per ADS - basic 139.2c 90.3c 470.7c 323.1c



Earnings per ordinary share -
diluted 44.4c 29.4c 150.9c 105.3c



Earnings per ADS - diluted 133.2c 88.2c 452.7c 315.9c



Weighted average number of
shares:

Millions Millions Millions Millions



Basic 550.7 547.7 551.1 546.2

Diluted 593.9 590.6 595.4 590.3



Unaudited US GAAP results for the three months and year to December 31, 2011
Consolidated Statements of Cash Flows



3 months to Year to
December 31, December 31,
2011 2010 2011 2010

$M $M $M $M

CASH FLOWS FROM OPERATING ACTIVITIES:



Net income 255.3 165.1 865.0 588.0

Adjustments to reconcile net income to net
cash provided by operating activities:

Depreciation and amortization 82.6 66.3 294.8 255.5

Share based compensation 21.0 18.0 75.7 62.2

Impairment of intangible assets - - 16.0 42.7

Gain on sale of non-current investments - - (23.5) (11.1)

Loss/(gain) on sale of product rights 2.2 (12.4) 6.0 (16.5)

Other 10.2 3.8 16.1 9.1

Movement in deferred taxes (1.3) (62.9) (14.5) (15.0)

Equity in losses/(earnings) of equity
method investees 0.7 (1.2) (2.5) (1.4)

Changes in operating assets and
liabilities:

(Increase)/decrease in accounts
receivable (11.3) 23.6 (134.0) (114.4)

Increase in sales deduction accrual 34.3 53.6 80.5 222.6

Increase in inventory (21.6) (4.1) (64.4) (58.2)

(Increase)/decrease in prepayments and
other assets (54.1) 26.7 (36.8) (40.3)

Increase/(decrease) in accounts payable
and other liabilities 91.4 66.4 (10.0) 25.9

Returns on investment from joint venture - - 5.2 5.8

Net cash provided by operating activities
(A) 409.4 342.9 1,073.6 954.9






CASH FLOWS FROM INVESTING ACTIVITIES:



Movements in restricted cash 0.5 553.3 6.2 6.3

Purchases of subsidiary undertakings,
net of cash acquired (1.5) (449.6) (725.0) (449.6)

Payments on foreign exchange contracts
related to Movetis - (12.2) - (33.4)

Purchases of non-current investments (2.4) (1.9) (10.7) (2.9)

Purchases of PP&E (58.4) (64.9) (194.3) (326.6)

Purchases of intangible assets - - (5.2) (2.7)

Proceeds from disposal of non-current
investments and PP&E 11.3 0.2 106.0 2.3

Proceeds/deposits received on sales of
product rights 3.2 2.0 12.0 2.0

Returns of equity investments and
proceeds from short term investments 0.1 7.2 1.8 7.2

Net cash (used in)/provided by investing
activities(B) (47.2) 34.1 (809.2) (797.4)





Unaudited US GAAP results for the three months and year to December 31, 2011
Consolidated Statements of Cash Flows (continued)



3 months to Year to
December 31, December 31,

2011 2010 2011 2010

$M $M $M $M



CASH FLOWS FROM FINANCING ACTIVITIES:



Proceeds from drawing of revolving credit
facility - - 30.0 -

Repayment of revolving credit facility - - (30.0) -

Repayment of debt acquired with ABH - - (13.1) -

Payment under building finance obligation (0.5) (0.5) (1.5) (2.4)

Extinguishment of building finance
obligation - - - (43.1)

Tax benefit/(loss) of stock based
compensation 7.7 (3.6) 31.4 6.5

Proceeds from exercise of options 12.5 9.5 13.4 11.2

Payment of facility arrangement costs - (8.0) - (8.0)

Payment of dividend (13.3) (12.2) (73.8) (62.0)

Payments to acquire shares by ESOT (25.0) - (151.8) (1.7)

Net cash used in financing activities(C) (18.6) (14.8) (195.4) (99.5)

Effect of foreign exchange rate changes on
cash and cash equivalents (D) - (4.9) 0.4 (6.3)

Net increase in cash and cash equivalents
(A) +(B) +(C) +(D) 343.6 357.3 69.4 51.7



Cash and cash equivalents at beginning of
period 276.4 193.3 550.6 498.9

Cash and cash equivalents at end of period 620.0 550.6 620.0 550.6



Unaudited US GAAP results for the three months and year to December 31, 2011

Selected Notes to the Financial Statements

(1) Earnings Per Share ("EPS")



3 months 3 months
to to Year to Year to
December December December December
31, 31, 31, 31,
2011 2010 2011 2010

$M $M $M $M



Numerator for basic EPS 255.3 165.1 865.0 588.0

Interest on convertible bonds,
net of tax 8.4 8.4 33.6 33.5



Numerator for diluted EPS 263.7 173.5 898.6 621.5





Weighted average number of
shares:

Millions Millions Millions Millions

Basic(1) 550.7 547.7 551.1 546.2

Effect of dilutive shares:

Stock options(2) 9.7 9.7 10.9 10.9

Convertible bonds 2.75% due 2014
(3) 33.5 33.2 33.4 33.2



Diluted 593.9 590.6 595.4 590.3




Excludes shares purchased by ESOT and presented by Shire as treasury stock.

Calculated using the treasury stock method.

Calculated using the "if converted" method.



The share equivalents not included in the calculation of the diluted weighted
average number of shares are shown below:



3 months to 3 months to Year to Year to
December 31, December 31, December 31, December 31,
2011 2010 2011 2010

Millions Millions Millions Millions

Share awards(1) 2.7 2.7 2.9 5.4




Certain stock options have been excluded from the calculation of diluted EPS
because (a) their exercise prices exceeded Shire's average share price during
the calculation period or (b) satisfaction of the required performance/market
conditions cannot be measured until the conclusion of the performance period.


Unaudited US GAAP results for the year to December 31, 2011

Selected Notes to the Financial Statements

(2) Analysis of revenues



Year to December 31, 2011 2010 2011 2011

% % of total

$M $M change Revenue

Net product sales:

Specialty Pharmaceutical ("SP")

ADHD

VYVANSE 805.0 634.2 27% 19%

ADDERALL XR 532.8 360.8 48% 12%

INTUNIV 223.0 165.9 34% 5%

EQUASYM 19.9 22.0 -10% <1%

DAYTRANA - 49.4 n/a n/a

1,580.7 1,232.3 28% 37%

Gastro Intestinal ("GI")

LIALDA/MEZAVANT 372.1 293.4 27% 9%

PENTASA 251.4 235.9 7% 6%

RESOLOR 6.1 0.3 n/a <1%

629.6 529.6 19% 15%

General products

FOSRENOL 166.9 182.1 -8% 4%

XAGRID® 90.6 87.3 4% 2%

CARBATROL® 52.3 82.3 -36% 1%

309.8 351.7 -12% 7%



Other product sales 95.5 105.6 -10% 2%

Total SP product sales 2,615.6 2,219.2 18% 61%



Human Genetic Therapies ("HGT")

REPLAGAL 475.2 351.3 35% 11%

ELAPRASE 464.9 403.6 15% 11%

VPRIV 256.2 143.0 79% 6%

FIRAZYR 33.0 11.1 197% 1%

Total HGT product sales 1,229.3 909.0 35% 29%



Regenerative Medicine ("RM")

DERMAGRAFT 105.3 - n/a 3%

Total RM product sales 105.3 - n/a 3%



Total product sales 3,950.2 3,128.2 26% 93%



Royalties:

ADDERALL XR 107.1 100.3 7% 2%

3TC and ZEFFIX 82.7 154.0 -46% 2%

FOSRENOL 46.5 26.8 74% 1%

Other 47.2 47.0 <1% 1%

Total royalties 283.5 328.1 -14% 6%



Other revenues 29.7 14.8 101% 1%



Total revenues 4,263.4 3,471.1 23% 100%





Unaudited US GAAP results for the three months to December 31, 2011

Selected Notes to the Financial Statements

(2) Analysis of revenues



3 months to December 31, 2011 2010 2011 2011

% % of total

$M $M change Revenue

Net product sales:

SP

ADHD

VYVANSE 217.1 180.6 20% 19%

ADDERALL XR 124.8 88.9 40% 11%

INTUNIV 65.4 42.9 52% 6%

EQUASYM 4.3 5.7 -25% <1%

411.6 318.1 29% 36%

GI

LIALDA/MEZAVANT 96.1 84.2 14% 8%

PENTASA 65.2 60.0 9% 6%

RESOLOR 2.1 0.3 n/a <1%

163.4 144.5 13% 14%

General products

FOSRENOL 39.9 44.7 -11% 3%

XAGRID 21.4 21.9 -2% 2%

CARBATROL 6.7 18.9 -65% <1%

68.0 85.5 -20% 6%



Other product sales 23.8 25.4 -6% 2%

Total SP product sales 666.8 573.5 16% 58%



HGT

ELAPRASE 124.0 106.2 17% 11%

REPLAGAL 120.9 109.3 11% 11%

VPRIV 69.3 59.0 17% 6%

FIRAZYR 14.9 3.4 338% 1%

Total HGT product sales 329.1 277.9 18% 29%



RM

DERMAGRAFT 53.3 - n/a 5%

Total RM product sales 53.3 - n/a 5%



Total product sales 1,049.2 851.4 23% 92%



Royalties:

ADDERALL XR 40.5 14.0 189% 4%

3TC and ZEFFIX 18.6 38.7 -52% 1%

FOSRENOL 15.1 8.6 76% 1%

Other 9.5 12.3 -23% 1%

Total royalties 83.7 73.6 14% 7%



Other revenues 9.3 6.2 50% 1%



Total revenues 1,142.2 931.2 23% 100%



Unaudited results for the year to December 31, 2011

Non GAAP reconciliation



US GAAP Adjustments Non GAAP



December Acquisitions Divestments, December
Year to, 31, Amortization & reorganizations 31,
& asset integration & discontinued Reclassify
2011 impairments activities operations depreciation 2011

(a) (b) (c) (d)

$M $M $M $M $M $M

Total revenues 4,263.4 - - - - 4,263.4

Costs and
expenses:

Cost of
product sales 588.1 - (11.0) (11.3) (33.2) 532.6

R&D 770.7 (16.0) - - (25.2) 729.5

SG&A 1,751.4 (165.0) - - (63.1) 1,523.3

Loss on sale
of product
rights 6.0 - - (6.0) - -

Reorganization
costs 24.3 - - (24.3) - -

Integration
and
acquisition
costs 13.7 - (13.7) - - -

Depreciation - - - - 121.5 121.5

Total
operating
expenses 3,154.2 (181.0) (24.7) (41.6) - 2,906.9



Operating
income 1,109.2 181.0 24.7 41.6 - 1,356.5



Interest
income 1.9 - - - - 1.9

Interest
expense (39.1) - - - - (39.1)

Other income/
(expense), net 18.1 2.4 - (23.5) - (3.0)

Total other
expense, net (19.1) 2.4 - (23.5) - (40.2)

Income before
income taxes
and equity in
earnings of
equity method
investees 1,090.1 183.4 24.7 18.1 - 1,316.3

Income taxes (227.6) (58.7) (8.3) 2.7 (291.9)

Equity in
earnings of
equity method
investees, net
of tax 2.5 - - - - 2.5

Net income 865.0 124.7 16.4 20.8 - 1,026.9

Impact of
convertible
debt, net of
tax 33.6 - - - - 33.6

Numerator for
diluted EPS 898.6 124.7 16.4 20.8 - 1,060.5

Weighted
average number
of shares
(millions) -
diluted 595.4 - - - - 595.4

Diluted
earnings per
ADS 452.7c 62.7c 8.4c 10.5c - 534.3c




The following items are included in Adjustments:

Amortization and asset impairments: Impairment of intangible assets ($16.0
million), amortization of intangible assets relating to intellectual property
rights acquired ($165.0 million), impairment of available for sale securities
($2.4 million), and tax effect of adjustments;

Acquisitions and integration activities: Unwind of ABH inventory fair value
adjustment ($11.0 million), costs associated with acquisition and integration
of ABH ($13.6 million) and integration of Movetis ($8.3 million), less
adjustment to contingent consideration payable for EQUASYM ($8.2 million),and
tax effect of adjustments;

Divestments, reorganizations and discontinued operations: Accelerated
depreciation ($6.6 million) and dual running costs ($4.7 million) on the
transfer of manufacturing from Owings Mills to a third party, re-measurement of
DAYTRANA contingent consideration to fair value ($6.0 million), reorganization
costs ($24.3 million) on the transfer of manufacturing from Owings Mills to a
third party and the establishment of an international commercial hub in
Switzerland, gain on disposal of investment in Vertex ($23.5 million), and tax
effect of adjustments; and

Depreciation: Depreciation of $121.5 million included in Cost of product sales,
R&D costs and SG&A costs for US GAAP separately disclosed for the presentation
of Non GAAP earnings.




Unaudited results for the year to December 31, 2010

Non GAAP reconciliation



US GAAP Adjustments Non GAAP



December Acquisitions Divestments, December
Year to, 31, Amortization & reorganizations 31,
& asset integration & discontinued Reclassify
2010 impairments activities operations depreciation 2010

(a) (b) (c) (d)

$M $M $M $M $M $M

Total revenues 3,471.1 - - - - 3,471.1

Costs and
expenses:

Cost of
product sales 463.4 - - (30.4) (12.4) 420.6

R&D 661.5 - (45.0) - (19.0) 597.5

SG&A 1,526.3 (176.2) - - (62.1) 1,288.0

Gain on sale
of product
rights (16.5) - - 16.5 - -

Reorganization
costs 34.3 - - (34.3) - -

Integration
and
acquisition
costs 8.0 - (8.0) - - -

Depreciation - - - - 93.5 93.5

Total
operating
expenses 2,677.0 (176.2) (53.0) (48.2) - 2,399.6



Operating
income 794.1 176.2 53.0 48.2 - 1,071.5



Interest
income 2.4 - - - - 2.4

Interest
expense (35.1) - - - - (35.1)

Other income/
(expense), net 7.9 - - (11.1) - (3.2)

Total other
expense, net (24.8) - - (11.1) - (35.9)

Income before
income taxes
and equity in
earnings of
equity method
investees 769.3 176.2 53.0 37.1 - 1,035.6

Income taxes (182.7) (38.9) (3.5) (13.5) - (238.6)

Equity in
earnings of
equity method
investees, net
of tax 1.4 - - - - 1.4

Net income 588.0 137.3 49.5 23.6 - 798.4

Impact of
convertible
debt, net of
tax 33.5 - - - - 33.5

Numerator for
diluted EPS 621.5 137.3 49.5 23.6 - 831.9

Weighted
average number
of shares
(millions) -
diluted 590.3 - - - - 590.3

Diluted
earnings per
ADS 315.9c 69.7c 25.1c 12.0c - 422.7c




The following items are included in Adjustments:

Amortization and asset impairments: Amortization of intangible assets relating
to intellectual property rights acquired ($133.5 million), impairment charge to
record DAYTRANA assets at fair value less costs to sell ($42.7 million) and tax
effect of adjustments;

Acquisitions and integration activities: Up-front payment to Acceleron ($45.0
million), acquisition costs ($8.0 million) primarily related to the Movetis
acquisition and tax effect of adjustments;

Divestments, reorganizations and discontinued operations:Accelerated
depreciation ($25.7 million) and dual running costs ($4.7 million) on the
transfer of manufacturing from Owings Mills to a third party, gain on sale of
non core product rights ($6.1 million), re-measurement of DAYTRANA contingent
consideration to fair value ($10.4 million), reorganization costs ($34.3
million) on the transfer of manufacturing from Owings Mills to a third party
and the establishment of an international commercial hub in Switzerland, gain
on disposal of the investment in Virochem ($11.1 million), and tax effect of
adjustments; and

Depreciation: Depreciation of $93.5 million included in Cost of product sales,
R&D costs and SG&A costs for US GAAP separately disclosed for the presentation
of Non GAAP earnings.




Unaudited results for the three months to December 31, 2011

Non GAAP reconciliation



US GAAP Adjustments Non GAAP



December Acquisitions Divestments, December
3 months to, 31, Amortization & reorganizations 31,
& asset integration & discontinued Reclassify
2011 impairments activities operations depreciation 2011

(a) (b) (c) (d)

$M $M $M $M $M $M

Total revenues 1,142.2 - - - - 1,142.2



Costs and
expenses:

Cost of
product sales 153.4 - (2.0) (2.3) (10.8) 138.3

R&D 214.4 - - - (8.8) 205.6

SG&A 456.1 (45.9) - (16.7) 393.5

Loss on sale
of product
rights 2.2 - - (2.2) - -

Reorganization
costs 6.3 - - (6.3) - -

Integration
and
acquisition
costs 5.8 - (5.8) - - -

Depreciation - - - - 36.3 36.3

Total
operating
expenses 838.2 (45.9) (7.8) (10.8) - 773.7



Operating
income 304.0 45.9 7.8 10.8 - 368.5



Interest
income 0.4 - - - - 0.4

Interest
expense (10.3) - - - - (10.3)

Other income,
net 2.2 - - - - 2.2

Total other
expense, net (7.7) - - - - (7.7)

Income before
income taxes
and equity in
losses of
equity method
investees 296.3 45.9 7.8 10.8 - 360.8

Income taxes (40.3) (23.1) (4.1) (1.8) - (69.3)

Equity in
losses of
equity method
investees, net
of tax (0.7) - - - - (0.7)

Net income 255.3 22.8 3.7 9.0 - 290.8

Impact of
convertible
debt, net of
tax 8.4 - - - - 8.4

Numerator for
diluted EPS 263.7 22.8 3.7 9.0 - 299.2

Weighted
average number
of shares
(millions) -
diluted 593.9 - - - - 593.9

Diluted
earnings per
ADS 133.2c 11.5c 1.9c 4.6c - 151.2c




The following items are included in Adjustments:

Amortization and asset impairments: Amortization of intangible assets relating
to intellectual property rights acquired ($45.9 million), and tax effect of
adjustments;

Acquisition and integration activities: Unwind of ABH inventory fair value
adjustment ($2.0 million), costs associated with the acquisition and
integration of ABH ($3.5 million) and integration of Movetis ($2.3 million),
and tax effect of adjustments;

Divestments, reorganizations and discontinued operations: Dual running costs
($2.3 million) on the transfer of manufacturing from Owings Mills to a third
party, re-measurement of DAYTRANA contingent consideration to fair value ($2.2
million), reorganization costs ($6.3 million) on the transfer of manufacturing
from Owings Mills to a third party and establishment of an international
commercial hub in Switzerland, and tax effect of adjustments; and

Depreciation: Depreciation of $36.3 million included in Cost of product sales,
R&D costs and SG&A costs for US GAAP separately disclosed for the presentation
of Non GAAP earnings.




Unaudited results for the three months to December 31, 2010

Non GAAP reconciliation



US GAAP Adjustments Non GAAP



December Acquisitions Divestments, December
3 months to, 31, Amortization & reorganizations 31,
& asset integration & discontinued Reclassify
2010 impairments activities operations depreciation 2010

(a) (b) (c) (d)

$M $M $M $M $M $M

Total revenues 931.2 - - - - 931.2



Costs and
expenses:

Cost of
product sales 129.7 - - (8.5) (3.8) 117.4

R&D 185.6 - - - (7.4) 178.2

SG&A 419.7 (33.9) - - (13.0) 372.8

Gain on sale
of product
rights (12.4) - - 12.4 - -

Reorganization
costs 11.0 - - (11.0) - -

Integration
and
acquisition
costs 1.6 - (1.6) - - -

Depreciation - - - - 24.2 24.2

Total
operating
expenses 735.2 (33.9) (1.6) (7.1) - 692.6



Operating
income 196.0 33.9 1.6 7.1 - 238.6



Interest
income 0.5 - - - - 0.5

Interest
expense (9.5) - - - - (9.5)

Other expense,
net (1.2) - - - - (1.2)

Total other
expense, net (10.2) - - - - (10.2)

Income before
income taxes
and equity in
earnings of
equity method
investees 185.8 33.9 1.6 7.1 - 228.4

Income taxes (21.9) (9.8) - (4.4) - (36.1)

Equity in
earnings of
equity method
investees, net
of tax 1.2 - - - - 1.2

Net income 165.1 24.1 1.6 2.7 - 193.5

Impact of
convertible
debt, net of
tax (1) 8.4 - - - - 8.4

Numerator for
diluted EPS 173.5 24.1 1.6 2.7 - 201.9

Weighted
average number
of shares
(millions) -
diluted 590.6 - - - - 590.6

Diluted
earnings per
ADS 88.2c 12.2c 0.8c 1.4c - 102.6c




The following items are included in Adjustments:

Amortization and asset impairments: Amortization of intangible assets relating
to intellectual property rights acquired ($33.9 million), and tax effect of
adjustments;

Acquisition and Integration activities: Costs associated with the acquisition
of Movetis ($1.6 million) and tax effect of adjustment;

Divestments, reorganizations and discontinued operations: Accelerated
depreciation ($7.4 million) and dual running costs ($1.1 million) on the
transfer of manufacturing from Owings Mills to a third party, re-measurement of
DAYTRANA contingent consideration to fair value ($10.4 million), gain on sale
of non-core product rights($2.0 million), reorganization costs ($11.0 million)
on the transfer of manufacturing from Owings Mills to a third party and
establishment of an international commercial hub in Switzerland, and tax effect
of adjustments; and

Depreciation: Depreciation of $24.2 million included in Cost of product sales,
R&D costs and SG&A costs for US GAAP separately disclosed for the presentation
of Non GAAP earnings.


Unaudited results for the three months and year to December 31, 2011

Non GAAP reconciliation



The following table reconciles US GAAP net cash provided by operating
activities to Non GAAP cash generation:



3 months to December Year to December
31, 31,

2011 2010 2011 2010

$M $M $M $M

Net cash provided by operating
activities 409.4 342.9 1,073.6 954.9

Tax and interest payments, net 37.4 51.3 317.4 352.9

Payments for acquired and
in-licensed products - - - 45.0

Non GAAP cash generation 446.8 394.2 1,391.0 1,352.8






The following table reconciles US GAAP net cash provided by operating
activities to Non GAAP free cashflow:



3 months to December Year to December
31, 31,
2011 2010 2011 2010

$M $M $M $M

Net cash provided by operating
activities 409.4 342.9 1,073.6 954.9

Payment for acquired and in-licensed
products - - - 45.0

Capital expenditure (1) (58.4) (64.9) (194.3) (204.7)

Non GAAP free cash flow 351.0 278.0 879.3 795.2




(1) Capital expenditure for the year ended December 31, 2010 excludes capital
expenditure relating to the acquisition of Lexington Technology Park.





Non GAAP net debt comprises:

December 31, December 31,
2011 2010

$M $M

Cash and cash equivalents 620.0 550.6

Restricted cash 20.6 26.8



Convertible bonds (1,100.0) (1,100.0)

Building finance obligation (8.2) (8.4)

Non GAAP net debt (467.6) (531.0)









NOTES TO EDITORS



THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995



Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks or
uncertainties materialize, Shire's results could be materially adversely
affected. The risks and uncertainties include, but are not limited to, risks
associated with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of Shire's Specialty
Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as
well as the ability to secure new products for commercialization and/or
development; government regulation of Shire's products; Shire's ability to
manufacture its products in sufficient quantities to meet demand; the impact of
competitive therapies on Shire's products; Shire's ability to register,
maintain and enforce patents and other intellectual property rights relating to
its products; Shire's ability to obtain and maintain government and other
third-party reimbursement for its products; and other risks and uncertainties
detailed from time to time in Shire's filings with the Securities and Exchange
Commission.


Non GAAP Measures



This press release contains financial measures not prepared in accordance with
US GAAP. These measures are referred to as "Non GAAP" measures and include: Non
GAAP operating income; Non GAAP net income; Non GAAP diluted earnings per ADS;
effective tax rate on Non GAAP income before income taxes and earnings/(losses)
of equity method investees ("Effective tax rate on Non GAAP income"); Non GAAP
cost of product sales; Non GAAP research and development; Non GAAP selling,
general and administrative; Non GAAP other income; Non GAAP cash generation;
Non GAAP free cashflow and Non GAAP net debt. These Non GAAP measures exclude
the effect of certain cash and non-cash items, that Shire's management believes
are not related to the core performance of Shire's business.



These Non GAAP financial measures are used by Shire's management to make
operating decisions because they facilitate internal comparisons of Shire's
performance to historical results and to competitors' results. Shire's
Remuneration Committee uses certain key Non GAAP measures when assessing the
performance and compensation of employees, including Shire's executive
directors.



The Non GAAP measures are presented in this press release as Shire's management
believe that they will provide investors with a means of evaluating, and an
understanding of how Shire's management evaluates, Shire's performance and
results on a comparable basis that is not otherwise apparent on a US GAAP
basis, since many non-recurring, infrequent or non-cash items that Shire's
management believe are not indicative of the core performance of the business
may not be excluded when preparing financial measures under US GAAP.



These Non GAAP measures should not be considered in isolation from, as
substitutes for, or superior to financial measures prepared in accordance with
US GAAP.



Where applicable the following items, including their tax effect, have been
excluded from both 2011 and 2010 Non GAAP earnings, and from our 2012 Outlook:



Amortization and asset impairments:

Intangible asset amortization and impairment charges; and

Other than temporary impairment of investments.



Acquisitions and integration activities:

Upfront payments and milestones in respect of in-licensed and acquired
products;

Costs associated with acquisitions, including transaction costs, fair value
adjustments on contingent consideration and acquired inventory;

Costs associated with the integration of companies; and

Noncontrolling interests in consolidated variable interest entities.



Divestments, re-organizations and discontinued operations:

Gains and losses on the sale of non-core assets;

Costs associated with restructuring and re-organization activities;

Termination costs; and

Income/(losses) from discontinued operations.



Depreciation, which is included in Cost of product sales, R&D and SG&A costs in
our US GAAP results, has been separately disclosed for the presentation of 2010
and 2011 Non GAAP earnings.



Cash generation represents net cash provided by operating activities, excluding
up-front and milestone payments for in-licensed and acquired products, tax and
interest payments.



Free cashflow represents net cash provided by operating activities, excluding
up-front and milestone payments for in-licensed and acquired products, but
including capital expenditure in the ordinary course of business.



A reconciliation of Non GAAP financial measures to the most directly comparable
measure under US GAAP is presented on pages 22 to 26.



Sales growth at CER, which is a Non GAAP measure, is computed by restating 2011
results using average 2010 foreign exchange rates for the relevant period.



Average exchange rates for the year to December 31, 2011 were $1.60:£1.00 and
$1.39:€1.00 (2010: $1.55:£1.00 and $1.33:€1.00). Average exchange rates for Q4
2011 were $1.57:£1.00 and $1.35:€1.00 (2010: $1.58:£1.00 and $1.36:€1.00).



TRADEMARKS



All trademarks designated ® and ™ used in this press release are trademarks of
Shire plc or companies within the Shire group except for 3TC® and ZEFFIX® which
are trademarks of GSK, PENTASA® which is a registered trademark of FERRING
B.V., FABRAZYME® and CEREZYME® which are trademarks of GENZYME CORPORATION and
DAYTRANA® which is a trade mark of Noven Pharmaceuticals Inc. Certain
trademarks of Shire plc or companies within the Shire group are set out in
Shire's Annual Report on Form 10-K for the year ended December 31, 2010 and the
Quarterly Report on Form 10-Q for the three months ended September 30, 2011.





END

Total Voting Rights

February 1, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, in accordance with DTR 5.6.1 of the FSA's Disclosure
and Transparency Rules, notifies the market of the following:

At close of business on January 31, 2012, Shire plc's issued voting share
capital consisted of 562,508,106 ordinary shares with a nominal value of 5
pence. Each ordinary share carries one voting right. Shire plc does not hold
any shares in Treasury.

The above figure (562,508,106) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Shire plc under the
FSA's Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary


For further information please contact:

Investor Eric Rojas (erojas@shire.com) +1 781 482 0999
Relations

Sarah Elton-Farr (seltonfarr@shire.com) +44 1256 894157

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder, human genetic
therapies, gastrointestinal diseases and regenerative medicine as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:
www.shire.com.


Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX


Press Release

www.shire.com



END

Full Year 2011 results date notification - February 9, 2012

Dublin, Ireland - January 31, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the
global specialty biopharmaceutical company, will announce full year 2011
earnings on Thursday February 9, 2012.

Results press release will be 12:00 GMT / 07:00 EST
issued at:

Investor conference call time: 14:00 GMT / 09:00 EST

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial
Officer will host the investor and analyst conference call at 14:00 GMT / 09:00
EST.

The details of the conference call are as follows:

UK dial in: 0800 077 8492 or 0844 335 0351

US dial in: 1 866 8048688 or 1 718 3541175

International dial in: +44 844 335 0351

Global Access Numbers: http://www.btconferencing.com/globalaccess/?bid=
54_attended

Password/Conf ID: 368 477

Live Webcast: http://www.shire.com/shireplc/en/investors

Replay:

A replay of the presentation will be available for two weeks by phone and by
webcast for one year. Details can be found on our Investor Relations website
http://www.shire.com/shireplc/en/investors.

For further information please contact:

Investor Relations Souheil Salah (ssalah@shire.com) +44 1256 894 160

Erin Kelly (erikelly@shire.com) +1 781 482 9541

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder, human genetic
therapies, gastrointestinal diseases and regenerative medicine, as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:
www.shire.com.


Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX


Press Release

www.shire.com



END

Press Release




Notification of major interests in shares



January 23, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company



1. Identity of the issuer or the underlying issuer of existing shares to which
voting rights are attached:



Shire plc



2. Reason for the notification State
Yes/No

An acquisition or disposal of voting rights Yes

An acquisition or disposal of financial instruments which may result in
the
acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify):




3. Full name of person(s) subject to the notification Capital Group
obligation: International, Inc.

4. Full name of shareholder(s) (if different from
3.):

5. Date of the transaction (and date on which the 19 January 2012
threshold is crossed
or reached if different):

6. Date on which issuer notified: 20 January 2012

7. Threshold(s) that is/are crossed or reached:

Below 3%

8. Notified details:




A: Voting rights attached to shares



Situation previous Resulting situation after the triggering
to transaction
the Triggering
transaction
Class/type of
shares Number Number Number Number of voting % of voting
if possible of of of rights rights
using the ISIN Shares Voting shares
CODE Rights

Direct Indirect Direct Indirect Direct Indirect

Ordinary 9,826,842 9,826,842 9,789,761 9,789,761 1.7405%

(JE00B2QKY057)

ADR 2,357,837 7,073,511 2,355,937 7,067,811 1.2566%

(US82481R1068)




B: Financial Instruments



Resulting situation after the triggering transaction



Type of Expiration Exercise/ Number of voting % of
financial date Conversion rights that may be voting
instrument Period/ Date acquired if the rights
instrument
is exercised/converted

n/a






Total (A+B)

Number of voting rights % of voting rights

16,857,572 2.9971%






9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

Number of Percent of
Shares Outstanding

Capital Group International, Inc. ("CGII") 16,857,572 2.9971%
holdings



Holdings by CGII Management Companies and
Funds:



• Capital Guardian Trust Company 14,035,752 2.4954%



• Capital International Limited 1,220,841 0.2170%



• Capital International SÁrl 293,119 0.0521%



• Capital International, Inc. 1,307,860 0.2325%




Proxy Voting:

10. Name of the proxy holder: N/A

11. Number of voting rights proxy holder will cease to hold: N/A

12. Date on which proxy holder will cease to hold voting rights: N/A




13. Additional information: Notification using the total voting rights figures
of

562,472,830



14. Contact name: Vivien Tan

15. Contact telephone (213) 615-0469
number:




Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, +44 1256 894746



For further information please contact:



Investor Relations Eric Rojas (erojas@shire.com) +1 781 482 0999

Sarah Elton-Farr (seltonfarr@shire.com) +44 1256 894157






Notes to editors



SHIRE PLC



Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder, human genetic
therapies, gastrointestinal diseases and regenerative medicine as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.



For further information on Shire, please visit the Company's website:
www.shire.com.



END